BRIEF—Biocad's new production complex producing the first series of drugs

The production complex PK-3 of Russian biotechnology company Biocad, which was launched in August 2021, has released the first batch of the finished dosage form - more than five hundred packs of the drug, intended for the treatment of patients with relapsing multiple sclerosis.

The new Biocad production complex is located on the territory of the Neudorf Special Economic Zone in St Petersburg. In August 2020, the company received a license from the Ministry of Industry and Trade of Russia for the production, storage and sale of solid dosage forms on the site, and on March 19, 2021, the Ministry of Industry and Trade issued a license for the production of active pharmaceutical ingredients at PK-3.

The launch of the site has become a strategic project for BIOCAD, which allowed the company to expand its production capacity, reduce costs for contract manufacturing and space rental. PK-3 concentrates the capacities for the development and production of chemical substances and solid dosage forms.